Market Overview:
The global cancer biopharmaceuticals market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for novel and targeted therapies, and growing focus on personalized medicine. The global cancer biopharmaceuticals market is segmented by type into biologics and biosimilars. The biologics segment is further divided into monoclonal antibodies (mAbs), cytokines, fusion proteins, erythropoietin (EPO), colony stimulating factors (CSFs), and interferons. The biosimilars segment is further divided into insulin analogues, somatropin analogues, follitropin alfa/beta analogues, luteinizing hormone receptor agonists/antagonists analogues GLP-1 receptor agonists/antagonists analoges erythropoietins analogue pegfilgrastim analogue G-CSF analogue granulocyte macrophage colony stimulating factor analogue Interleukins IL-2 IL-4 IL-6 IL-10). By application, the global cancer biopharmaceuticals market is classified as liquid cancers and solid cancers.
Product Definition:
Cancer biopharmaceuticals are drugs that are made from biological sources, such as human cells or tissues. Cancer biopharmaceuticals can be used to treat cancer or to prevent it from spreading. They may also be used to improve the quality of life for cancer patients.
Biologics:
Biologics are living organisms or products derived from living organisms and used as therapeutic agents in diseases. Biologics act through the immune system by attaching themselves to tumor cells and destroying them. Some biologics like monoclonal antibodies can attach themselves to cancer cells, while others like interleukin (IL) can block the action of mTOR which is a signaling pathway that helps tumors grow.
Biosimilars:
Biosimilars are biological products that are highly similar to an original biologic drug. They have the same mechanism of action, dosage, and route of administration as the origin product. Biosimilar drugs can be considered as a generic version of origin drugs with improved therapeutic value.
Application Insights:
The oncology segment dominated the global cancer biopharmaceuticals market in 2017. This is owing to the rising prevalence of cancer and increasing investment by companies for R&D pertaining to this disease. For instance, in September 2016, Merck KGaA announced about entering into a collaboration with University of California (UC) for discovering and developing novel targeted therapies for solid tumors such as non-small cell lung cancer and pancreatic ductal adenocarcinoma.
Furthermore, constant advancements in technology have led to an increase in investments made by companies such as Pfizer Inc., Novartis AG et al. These players are continuously investing money not only on research but also on marketing activities regarding their drugs which is expected to boost product demand over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. Key factors contributing to this dominance are increasing R&D expenditure, presence of key players, and high incidence rate of cancer among the U.S population. In addition, growing focus on drug development by companies such as Pfizer Inc., Merck & Co., Inc., Celgene Corporation is also expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to increase in healthcare spending by governments coupled with rise in awareness about early diagnosis of cancers and effective treatment options available for them.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the global cancer biopharmaceuticals market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 609,640 people will die from this disease. This high incidence rate of cancer is expected to drive demand for novel and innovative treatment options such as cancer biopharmaceuticals products over the forecast period.
- Rising prevalence of lifestyle-associated cancers: The rising prevalence of lifestyle-associated cancers such as obesity-related cancers and tobacco-related cancers is also anticipated to fuel demand forcancer biopharmaceuticals products over the forecast period. For instance, according to a study published in Lancet Oncology in 2016, it was found that obesity accounts for 18%–20%of all incident cases globallyof common adult cancers including breast (postmenopausal), colorectal (CRC), endometrial (uterine), kidney (renal cell carcinoma), esophageal adenocarcinoma) liver (hepatocellular carcinoma [HCC]), ovarian(epithelial ovarian carcinomas [EOC]), pancreatic(pancreatic ductal adenocarcinomas [PDAC])and prostate(prostate adenocarcinomas).
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Biopharmaceuticals Market Research Report
By Type
Biologics, Biosimilars
By Application
Liquid Cancers, Solid Cancers
By Companies
Sanofi, Johnson & Johnson, Pfizer, Novartis, Merck, GlaxoSmithKline, Eli Lilly, Agios Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
197
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Biopharmaceuticals Market Report Segments:
The global Cancer Biopharmaceuticals market is segmented on the basis of:
Types
Biologics, Biosimilars
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Liquid Cancers, Solid Cancers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Johnson & Johnson
- Pfizer
- Novartis
- Merck
- GlaxoSmithKline
- Eli Lilly
- Agios Pharmaceuticals
- Bristol-Myers Squibb
- AstraZeneca
- Mylan
- LEO Pharma
- Boehringer Ingelheim
- Alexion Pharmaceuticals
- Elusys Therapeutics
Highlights of The Cancer Biopharmaceuticals Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Biologics
- Biosimilars
- By Application:
- Liquid Cancers
- Solid Cancers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Biopharmaceuticals Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer Biopharmaceuticals is a company that manufactures and sells cancer drugs.
Some of the major players in the cancer biopharmaceuticals market are Sanofi, Johnson & Johnson, Pfizer, Novartis, Merck, GlaxoSmithKline, Eli Lilly, Agios Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics.
The cancer biopharmaceuticals market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Biopharmaceuticals Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Biopharmaceuticals Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Biopharmaceuticals Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Biopharmaceuticals Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Biopharmaceuticals Market Size & Forecast, 2018-2028
4.5.1 Cancer Biopharmaceuticals Market Size and Y-o-Y Growth
4.5.2 Cancer Biopharmaceuticals Market Absolute $ Opportunity
Chapter 5 Global Cancer Biopharmaceuticals Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cancer Biopharmaceuticals Market Size Forecast by Type
5.2.1 Biologics
5.2.2 Biosimilars
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cancer Biopharmaceuticals Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cancer Biopharmaceuticals Market Size Forecast by Applications
6.2.1 Liquid Cancers
6.2.2 Solid Cancers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Biopharmaceuticals Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Biopharmaceuticals Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cancer Biopharmaceuticals Analysis and Forecast
9.1 Introduction
9.2 North America Cancer Biopharmaceuticals Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cancer Biopharmaceuticals Market Size Forecast by Type
9.6.1 Biologics
9.6.2 Biosimilars
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cancer Biopharmaceuticals Market Size Forecast by Applications
9.10.1 Liquid Cancers
9.10.2 Solid Cancers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cancer Biopharmaceuticals Analysis and Forecast
10.1 Introduction
10.2 Europe Cancer Biopharmaceuticals Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cancer Biopharmaceuticals Market Size Forecast by Type
10.6.1 Biologics
10.6.2 Biosimilars
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cancer Biopharmaceuticals Market Size Forecast by Applications
10.10.1 Liquid Cancers
10.10.2 Solid Cancers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cancer Biopharmaceuticals Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cancer Biopharmaceuticals Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cancer Biopharmaceuticals Market Size Forecast by Type
11.6.1 Biologics
11.6.2 Biosimilars
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cancer Biopharmaceuticals Market Size Forecast by Applications
11.10.1 Liquid Cancers
11.10.2 Solid Cancers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cancer Biopharmaceuticals Analysis and Forecast
12.1 Introduction
12.2 Latin America Cancer Biopharmaceuticals Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cancer Biopharmaceuticals Market Size Forecast by Type
12.6.1 Biologics
12.6.2 Biosimilars
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cancer Biopharmaceuticals Market Size Forecast by Applications
12.10.1 Liquid Cancers
12.10.2 Solid Cancers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cancer Biopharmaceuticals Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cancer Biopharmaceuticals Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cancer Biopharmaceuticals Market Size Forecast by Type
13.6.1 Biologics
13.6.2 Biosimilars
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cancer Biopharmaceuticals Market Size Forecast by Applications
13.10.1 Liquid Cancers
13.10.2 Solid Cancers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Biopharmaceuticals Market: Competitive Dashboard
14.2 Global Cancer Biopharmaceuticals Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Johnson & Johnson
14.3.3 Pfizer
14.3.4 Novartis
14.3.5 Merck
14.3.6 GlaxoSmithKline
14.3.7 Eli Lilly
14.3.8 Agios Pharmaceuticals
14.3.9 Bristol-Myers Squibb
14.3.10 AstraZeneca
14.3.11 Mylan
14.3.12 LEO Pharma
14.3.13 Boehringer Ingelheim
14.3.14 Alexion Pharmaceuticals
14.3.15 Elusys Therapeutics
